Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Share:
Related NBIX
JP Morgan Initiates Neurocrine Biosciences With Overweight
Benzinga's Top Initiations

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Latest Ratings for NBIX

DateFirmActionFromTo
Mar 2015JP MorganInitiates Coverage onOverweight
Mar 2015BarclaysInitiates Coverage onOverweight
Feb 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (NBIX)

Around the Web, We're Loving...

Get Benzinga's Newsletters